Auto-Inflammatory Syndromes : Pathophysiology, Diagnosis, and Management
https://libcat.nshealth.ca/en/permalink/provcat44069
Petros Efthimiou, editor.
--Cham:
Springer
, 2019.
- Available Online
- View e-Book
- Location
- Online
This book provides an overview of auto-inflammatory syndromes, covering the underlying immune mechanisms that lead to their development, specific disease presentations, and clinical treatment guidelines. The book is divided into two sections, adult and pediatric, with chapters focusing on individuals diseases such as systemic arthritis, hyper-IgD, pap syndrome, idiopathic recurrent pericarditis, and familial Mediterranean fever. Chapters incorporate the most recent advances in disease pathophys…
- Available Online
- View e-Book
- Other Authors
- Efthimiou, Petros
- Responsibility
- Petros Efthimiou, editor
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- 2019
- Physical Description
- 1 online resource (xix, 322 p.) : 39 illus., 31 illus. in color
- ISBN
- 9783319969299
- 9783319969282 (Print ed.)
- 9783319969305 (Print ed.)
- Subjects (MeSH)
- Autoimmune Diseases
- Hereditary Autoinflammatory Diseases
- Inflammation - physiopathology
- Specialty
- Allergy and Immunology
- Abstract
- This book provides an overview of auto-inflammatory syndromes, covering the underlying immune mechanisms that lead to their development, specific disease presentations, and clinical treatment guidelines. The book is divided into two sections, adult and pediatric, with chapters focusing on individuals diseases such as systemic arthritis, hyper-IgD, pap syndrome, idiopathic recurrent pericarditis, and familial Mediterranean fever. Chapters incorporate the most recent advances in disease pathophysiology and examine the underlying inductive and effector mechanisms and therapies that relate to each auto-inflammatory disorder at the genetic, molecular, cellular, and epidemiologic levels. The book also discusses the research behind auto-inflammatory disorders to offer detailed clinical guidelines regarding diagnostic techniques, treatment plans, and advice on how to best transition pediatric patients into adult treatment. This is an invaluable reference on auto-inflammatory syndromes for clinicians and researchers in pediatric and adult rheumatology and immunology.
- Contents
- 1. Immunology of Auto-inflammatory Syndromes -- Part I. Monogenic Autoinflammatory Diseases -- 2. Mevalonate Kinase Deficiency (MKD)/Hyperimmunoglobulin D Syndrome (HIDS) -- 3. The TNF Receptor-Associated Autoinflammatory Syndrome (TRAPS) -- 4. PAPA Syndrome and the Spectrum of PSTPIP1-Associated Inflammatory Diseases -- 5. Blau Syndrome -- 6. Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) -- 7. Deficiency of the Interleukin-36 Receptor Antagonist (DITRA) and Generalized Pustular Psoriasis -- 8. Cryopyrin-Associated Periodic Syndromes (CAPS) -- 9. Familial Mediterranean Fever -- 10. Type I Interferonopathies: From Pathophysiology to Clinical Expression -- 11. Deficiency of Adenosine Deaminase 2 (DADA2) -- 12. Yao Syndrome -- Part II. Polygenic Autoinflammatory Diseases -- 13. Systemic Juvenile Idiopathic Arthritis -- 14. Macrophage Activation Syndrome (MAS) -- 15. Schnitzler Syndrome -- 16. Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome -- 17. Chronic Nonbacterial Osteomyelitis -- 18. Improving the Transition from Pediatric to Adult Care for Adolescents and Young Adults with Autoinflammatory Diseases -- 19. Adult-Onset Still’s Disease - 20. Idiopathic Recurrent Acute Pericarditis -- 21. Adamantiades-Behçet’s Disease -- 22. Amyloidosis.
- Format
- e-Book
- Location
- Online
Hormone Therapy and Castration Resistance of Prostate Cancer
https://libcat.nshealth.ca/en/permalink/provcat42814
Yoichi Arai, Osamu Ogawa, editors.
--Singapore:
Springer
, c2018.
- Available Online
- View e-Book
- Location
- Online
This comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and…
- Available Online
- View e-Book
- Other Authors
- Arai, Yoichi
- Ogawa, Osamu
- Responsibility
- Yoichi Arai, Osamu Ogawa, editors
- Place of Publication
- Singapore
- Publisher
- Springer
- Date of Publication
- c2018
- Physical Description
- 1 online resource (viii, 433 p.) : 65 illus., 34 illus. in color
- ISBN
- 9789811070136
- 9789811070129 (print ed.)
- 9789811070143 (print ed.)
- Subjects (MeSH)
- Antineoplastic Agents, Hormonal - therapeutic use
- Prostatic Neoplasms, Castration-Resistant - drug therapy
- Specialty
- Endocrinology
- Medical Oncology
- Urology
- Abstract
- This comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged. During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnic variation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa.
- Contents
- 1. Introduction -- 2. Recent trends in hormone therapy for prostate cancer in Japan -- 3. Risk assessment among patients receiving primary ADT -- 4. Patient-derived xenografts for research on hormonal therapy of prostate cancer -- 5. Impact of GnRH antagonist and LHRH agonist on the gonadal axis -- 6. Controversies on complete androgen blockade -- 7. Adrenal androgen in prostate cancer -- 8. Intermittent ADT for prostate cancer -- 9. Pognostic significance of monitoring serum testosterone in primary ADT -- 10. Ethnic variation in clinical outcomes of primary ADT for prostate cancer -- 11. ADT in combination with radical prostatectomy -- 12. ADT in combination with radiation therapy -- 13. ADT as salvage therapy after definitive treatment -- 14. ADT for clinically localised prostate cancer -- 15. Complications of ADT -- 16. Hot flash -- 17. Oseteoporosis and fracture risk -- 18. Metaboplic change -- 19. Bone scan index as a biomarker of bone metastasis -- 20. Genetic polymorphism analysis in predicting prognosis of metastatic prostate cancer -- 21. Local therapy in combination with ADT for metastatic prostate cancer -- 22. Oxidative stress and CRPC -- 23. Alternative antiandrogen therapy for CRPC -- 24. Optimization of sequential AR targeted therapy for CRPC -- 25. Enzalutamide therapy for mCRPC in Japanese men -- 26. Abiraterone acetate therapy for mCRPC in Japanese men -- 27. Role of estramustine phosphate for CRPC -- 28. Steroid therapy for CRPC -- 29. MicroRNA analysis in prostate cancer -- 30. AR splicing variant in prostate cancer -- 31. Detection of CTC in CRPC -- 32. New biomarker for CRPC: Glycobiologic perspective -- 33. Bone-tageted treatment in CRPC management -- 34. Skeletal complications in CRPC patients -- 35. Urological complications in men dying from prostate cancer -- 36. Prediction of optimal docetaxel regimen for patients with mCRPC -- 37. Intermittent chemotherapy with decetaxel for mCRPC -- 38. Chemotherapy with cabazitaxel for ìCRPC in Japanese men -- 39. New tageted approach to CRPC -- 40. Molecular basis of neuroendocrine prostate cancer -- 41. Gene therapy for prostate cancer -- 42. Immune therapy for CRPC -- 43. New approach to CRPC using inactivated virus -- 44. Patient-reported outcome in the management of CRPC.
- Format
- e-Book
- Location
- Online
Atrial Fibrillation and Percutaneous Coronary Intervention : A Case-based Guide to Oral Anticoagulation, Antiplatelet Therapy and Stenting
https://libcat.nshealth.ca/en/permalink/provcat41420
Andrea Rubboli, Gregory Y. H. Lip, editors.
--Cham:
Springer
, 2017.
- Available Online
- View e-Book
- Location
- Online
This book considers paradigmatic clinical cases in order to cast light on key issues relating to elective or emergency stent implantation and the use of oral anticoagulation (OAC) in patients with atrial fibrillation. The topics addressed include the optimal periprocedural antithrombotic treatment (uninterrupted vs interrupted OAC, intraprocedural use of heparin and glycoprotein IIb/IIIa inhibitors, etc.), the most appropriate type of stent (bare metal vs drug eluting vs "bioactive"), the optim…
- Available Online
- View e-Book
- Other Authors
- Rubboli, Andrea
- Lip, Gregory Y. H.
- Responsibility
- Andrea Rubboli, Gregory Y. H. Lip, editors
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- 2017
- Physical Description
- 1 online resource (viii, 212 pages) : 52 illus., 30 illus. in color
- ISBN
- 9783319424002
- 9783319423982 (print ed.)
- Subjects (MeSH)
- Anticoagulants - therapeutic use
- Atrial Fibrillation - drug therapy
- Atrial Fibrillation - surgery
- Percutaneous Coronary Intervention - methods
- Vitamin K - therapeutic use
- Abstract
- This book considers paradigmatic clinical cases in order to cast light on key issues relating to elective or emergency stent implantation and the use of oral anticoagulation (OAC) in patients with atrial fibrillation. The topics addressed include the optimal periprocedural antithrombotic treatment (uninterrupted vs interrupted OAC, intraprocedural use of heparin and glycoprotein IIb/IIIa inhibitors, etc.), the most appropriate type of stent (bare metal vs drug eluting vs "bioactive"), the optimal regimen (e.g., triple therapy of OAC, aspirin, and clopidogrel vs the combination of OAC and a single antiplatelet agent), and the most suitable duration of the antithrombotic treatment prescribed at discharge (1 vs 6-12 months). The case-based management recommendations will be of wide practical value in the current health care context, where percutaneous coronary intervention is available even to patients with relevant co-morbidities, such as those warranting long-term OAC, and the indications for OAC are much broader than in the past. The book will appeal especially to clinical and interventional cardiologists, internal medicine specialists, hematologists, and family physicians and will also be of interest to cardiology and internal medicine residents and fellows.
- Contents
- Atrial fibrillation on vitamin K-antagonists undergoing elective coronary artery stenting for stable effort angina -- Atrial fibrillation on NOAC (dabigatran) undergoing elective coronary artery stenting for stable effort angina -- Atrial fibrillation on vitamin K-antagonist undergoing urgent coronary stenting for non ST-elevation acute coronary syndrome -- Atrial fibrillation on NOAC (rivaroxaban) undergoing urgent coronary stenting for non ST-elevation acute coronary syndrome -- Atrial fibrillation on vitamin K-antagonist undergoing emergency primary coronary stenting for ST-elevation acute myocardial infarction -- Atrial fibrillation on NOAC (apixaban) undergoing emergency primary coronary stenting for ST-elevation acute myocardial infarction -- Atrial fibrillation early complicating acute coronary syndrome treated with coronary artery stenting -- New-onset atrial fibrillation in a stable patient with remote coronary artery stenting -- Urgent surgery early after coronary stenting in a patient with atrial fibrillation on triple therapy of warfarin, aspirin and clopidogrel -- Urgent surgery early after coronary stenting in a patjent with atrial fibrillation on triple therapy of NOAC (a factor Xa-inhibitor), aspirin and clopidogrel -- Major bleeding early after coronary stenting in a patient with atrial fibrillation on triple therapy of warfarin, aspirin and clopidogrel -- Major bleeding early after coronary stenting in a patient with atrial fibrillation on triple therapy of NOAC (dabigatran), aspirin and clopidogrel.
- Format
- e-Book
- Location
- Online
Treatment of Non-vitamin K Antagonist Oral Anticoagulants : For Prevention of Stroke
https://libcat.nshealth.ca/en/permalink/provcat41950
Masaaki Uno, Kuniaki Ogasawara, editors.
--Singapore:
Springer
, 2017.
- Available Online
- View e-Book
- Location
- Online
This book describes new concepts and strategies for the clinical application of non-vitamin K antagonist oral anticoagulants (NOACs) for stroke. Although vitamin K antagonists have traditionally been used for the prevention of stroke, there are some problems associated with their use, such as the risk of intracranial hemorrhage, the need for dietary restrictions, and individual variability. Recently, NOACs have been introduced as alternatives to traditional anticoagulants and are becoming an op…
- Available Online
- View e-Book
- Other Authors
- Uno, Masaaki
- Ogasawara, Kuniaki
- Responsibility
- Masaaki Uno, Kuniaki Ogasawara, editors
- Place of Publication
- Singapore
- Publisher
- Springer
- Date of Publication
- 2017
- Physical Description
- 1 online resource (ix, 99 pages) : 31 illus., 13 illus. in color
- ISBN
- 9789811018787
- 9789811018770 (print ed.)
- Subjects (MeSH)
- Anticoagulants - therapeutic use
- Stroke - prevention & control
- Vitamin K - antagonists & inhibitors
- Abstract
- This book describes new concepts and strategies for the clinical application of non-vitamin K antagonist oral anticoagulants (NOACs) for stroke. Although vitamin K antagonists have traditionally been used for the prevention of stroke, there are some problems associated with their use, such as the risk of intracranial hemorrhage, the need for dietary restrictions, and individual variability. Recently, NOACs have been introduced as alternatives to traditional anticoagulants and are becoming an option for treating stroke patients around the globe. However, their use is not without risk. Each chapter describes the successful use of NOACs for stroke patients and discusses their future impact from various points of view. The book is primarily written for neurosurgeons and neurologists but is also of interest to cardiologists involved in stroke treatment.
- Contents
- 1 .Intracranial Bleeding -- 2. Severity and Outcomes of Intracerebral Bleeding and Cardiac Cerebral Embolism -- 3. Influence for Intracranial Bleeding Surgery -- 4. New Approaches for the Secondary Prevention of Cryptogenic Stroke Using Non-Vitamin K Antagonist Oral Anticoagulants -- 5. Secondary Prevention of Cerebral Infarct: Verification of Appropriateness in Choices of Anticoagulant by Comparison of Current and previous Treatment Results -- 6. Putaminal Hemorrhage in Patients with Oral Anticoagulants -Course of Treatment and Results of Endoscopic Evacuation -- 7. Secondary Prevention of Stroke with Atrial Fibrillation by New Oral Anticoagulants -- 8. Causes and Outcome in Patients with Cerebral Hemorrhage Using Anticoagulated Drugs.
- Format
- e-Book
- Location
- Online
Diagnosis and Treatment of Pulmonary Hypertension : From Bench to Bedside
https://libcat.nshealth.ca/en/permalink/provcat42004
Yoshihiro Fukumoto, editor.
--Singapore:
Springer
, 2017.
- Available Online
- View e-Book
- Location
- Online
This book focuses on pulmonary arterial hypertension (PAH, Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, Group 4) among the various groups of pulmonary hypertension (PH) whose classification was updated into five major categories at the 5th World Symposium held in Nice, France, in 2013. Readers will find recent progress, methods, and up-to-date information on PH mechanisms, diagnostic images, and treatment in the management of PH. This volume, with contributions by leading …
- Available Online
- View e-Book
- Other Authors
- Fukumoto, Yoshihiro
- Responsibility
- Yoshihiro Fukumoto, editor
- Place of Publication
- Singapore
- Publisher
- Springer
- Date of Publication
- 2017
- Physical Description
- 1 online resource (viii, 236 pages) : 70 illus., 45 illus. in color
- ISBN
- 9789812878403
- 9789812878397 (print ed.)
- Subjects (MeSH)
- Hypertension, Pulmonary - diagnosis
- Hypertension, Pulmonary - therapy
- Abstract
- This book focuses on pulmonary arterial hypertension (PAH, Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, Group 4) among the various groups of pulmonary hypertension (PH) whose classification was updated into five major categories at the 5th World Symposium held in Nice, France, in 2013. Readers will find recent progress, methods, and up-to-date information on PH mechanisms, diagnostic images, and treatment in the management of PH. This volume, with contributions by leading researchers worldwide in the field , consists of five parts, starting with the fundamentals of PH, then pathophysiology and genetics, treatment, and right ventricular function.
- Contents
- Part I: Fundamentals of Pulmonary Hypertension -- 1. Clinical Classification -- 2. Diagnosis: Imagings -- Part II: Pathophysiology and Genetics -- 3. Pathogenic and Therapeutic Role of MicroRNA in Pulmonary Arterial Hypertension -- 4. Sex Hormones -- 5. Rho-Kinase -- 6. The Unique Property of the Pulmonary Artery Regarding the Smooth Muscle Effects of Proteinase-activated Receptor 1: The Possible Contribution to the Pathogenesis of Pulmonary Hypertension -- 7. Animal Models with Pulmonary Hypertension -- 8. Human Pathology -- 9. Pathophysiology and Genetics: BMPR2 -- Part III: Treatment of Pulmonary Arterial Hypertension (PAH) -- 10. Prostacyclin -- 11. Targeting the NO-sGC-cGMP pathway in pulmonary arterial hypertension -- 12. Endothelin Receptor Antagonist -- 13. Lung Transplantation -- Part IV: Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) -- 14. Medical Therapy for Chronic Thromboembolic Pulmonary Hypertension -- 15. Balloon Pulmonary Angioplasty -- 16. Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension -- Part V: Right Ventricular Function -- 17. Right Ventricular Function.
- Format
- e-Book
- Location
- Online
Non-Vitamin K Antagonist Oral Anticoagulants : A Concise Guide
https://libcat.nshealth.ca/en/permalink/provcat39979
Eduard Shantsila, Gregory YH Lip.
--Cham:
SpringerOpen ; Adis
, c2016.
- Available Online
- View e-Book
- Access
- Open access
- Location
- Online
This book is an essential guide to the medical treatment of thrombosis and presents core principles of anticoagulant therapeutics as well as drug recommendations. Written by recognized experts in the field, this concise, accessible handbook provides a unique and valuable resource in the cardiovascular field, both for those currently in training, and for those already in clinical or research practice.
- Available Online
- View e-Book
- Author
- Shantsila, Eduard
- Other Authors
- Lip, Gregory YH
- Responsibility
- Eduard Shantsila, Gregory YH Lip
- Place of Publication
- Cham
- Publisher
- SpringerOpen ; Adis
- Date of Publication
- c2016
- Physical Description
- 1 online resource (x, 50 p.) : 13 illus., 7 illus. in color
- ISBN
- 9783319254609
- 9783319254586 (print ed.)
- Subjects (MeSH)
- Anticoagulants - therapeutic use
- Antithrombins - therapeutic use
- Factor Xa Inhibitors - therapeutic use
- Specialty
- Hematology
- Pharmacology
- Abstract
- This book is an essential guide to the medical treatment of thrombosis and presents core principles of anticoagulant therapeutics as well as drug recommendations. Written by recognized experts in the field, this concise, accessible handbook provides a unique and valuable resource in the cardiovascular field, both for those currently in training, and for those already in clinical or research practice.
- Contents
- 1. Introduction -- 2. Direct thrombin inhibitors -- 3. Factor Xa inhibitors -- 4. Conclusions.
- Access
- Open access
- Format
- e-Book
- Location
- Online
Management of Chemotherapy-Induced Nausea and Vomiting : New Agents and New Uses of Current Agents
https://libcat.nshealth.ca/en/permalink/provcat40025
Rudolph M. Navari, editor.
(1st ed.)
--Cham:
Springer International Publishing : Imprint: Adis
, c2016.
- Available Online
- View e-Book
- Location
- Online
This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past …
- Available Online
- View e-Book
- Other Authors
- Navari, Rudolph M
- Responsibility
- Rudolph M. Navari, editor
- Edition
- 1st ed.
- Place of Publication
- Cham
- Publisher
- Springer International Publishing : Imprint: Adis
- Date of Publication
- c2016
- Physical Description
- 1 online resource (viii, 181 p. : 17 illus., 9 illus. in color)
- ISBN
- 9783319270166
- 9783319270142 (print ed.)
- Subjects (MeSH)
- Antiemetics - therapeutic use
- Drug-Related Side Effects and Adverse Reactions
- Nausea - chemically induced
- Nausea - drug therapy
- Neoplasms - drug therapy
- Vomiting - chemically induced
- Vomiting - drug therapy
- Abstract
- This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients' perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.
- Contents
- 1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions.
- Format
- e-Book
- Location
- Online
Ketamine for Treatment-Resistant Depression : The First Decade of Progress
https://libcat.nshealth.ca/en/permalink/provcat40316
Sanjay J. Mathew, Carlos A. Zarate, Jr., editors.
--Cham:
Springer International Publishing : Imprint: Adis
, c2016.
- Available Online
- View e-Book
- Location
- Online
This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation "ketamine-like" fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of seve…
- Available Online
- View e-Book
- Other Authors
- Mathew, Sanjay J
- Zarate, Jr., Carlos A
- Responsibility
- Sanjay J. Mathew, Carlos A. Zarate, Jr., editors
- Place of Publication
- Cham
- Publisher
- Springer International Publishing : Imprint: Adis
- Date of Publication
- c2016
- Physical Description
- 1 online resource (xix, 155 p. : 6 illus., 3 illus. in color)
- ISBN
- 9783319429250
- 9783319429236 (print ed.)
- Subjects (MeSH)
- Antidepressive Agents
- Depressive Disorder, Major - drug therapy
- Depressive Disorder, Treatment-Resistant - drug therapy
- Ketamine - therapeutic use
- Abstract
- This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation "ketamine-like" fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine's psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine's rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine's rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.
- Contents
- 1. The History of Ketamine Use and Its Clinical Indications -- 2. The Basic and Clinical Pharmacology of Ketamine -- 3. Ketamine: Clinical Studies in Treatment- Resistant Depressive Disorders -- 4. Ketamine and Suicide Risk -- 5. Ketamine: Its Safety, Tolerability, and Impact on Neurocognition -- 6. Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies -- 7. Ketamine’s Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies -- 8. Ketamine and Electroconvulsive Therapy -- 9. Emerging Data for Ketamine in Obsessive-Compulsive, Stress-Related, and Substance Use Disorders.
- Format
- e-Book
- Location
- Online
Cardiac Drug Therapy
https://libcat.nshealth.ca/en/permalink/provcat39040
M. Gabriel Khan.
(8th ed.)
--Totowa, NJ:
Humana Press
, c2015.
- Available Online
- View e-Book
- Location
- Online
This book is an essential guide to the medical treatment of the cardiac patient and presents core principles of cardiovascular therapeutics as well as drug recommendations. Major classes of drugs are featured, including beta-blockers, ACE inhibitors, calcium antagonists, diuretics, and antiplatelet agents and unique insights into the controversies surrounding the use of specific drugs are explored, with answers given to the question: do beta blockers and diuretics really cause diabetes? Propert…
- Available Online
- View e-Book
- Author
- Khan, M. Gabriel
- Responsibility
- M. Gabriel Khan
- Edition
- 8th ed.
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2015
- Physical Description
- 1 online resource (xxxii, 791 p. : 44 illus., 6 illus. in color)
- Series Title
- Contemporary cardiology
- ISBN
- 9781617799624
- 9781617799617 (print ed.)
- ISSN
- 2196-8969
- Subjects (MeSH)
- Cardiovascular Agents - therapeutic use
- Heart Diseases - drug therapy
- Abstract
- This book is an essential guide to the medical treatment of the cardiac patient and presents core principles of cardiovascular therapeutics as well as drug recommendations. Major classes of drugs are featured, including beta-blockers, ACE inhibitors, calcium antagonists, diuretics, and antiplatelet agents and unique insights into the controversies surrounding the use of specific drugs are explored, with answers given to the question: do beta blockers and diuretics really cause diabetes? Properties, dosage, side effects, potential salutary benefits, and drawbacks on virtually all commercially available cardiac drugs are examined. This revised edition is thoroughly updated and addresses the entire spectrum of heart disorders, such as hypertension, angina, myocardial infarction, heart failure, arrhythmias, cardiac arrest, and dyslipidemias. New chapters include endocrine heart diseases, management of cardiomyopathies, and newer agents. In addition, topics such as cardiac drugs in pregnancy and lactation and drug interactions are covered. Cardiac Drug Therapy, Eighth Edition, is an authoritative and clinically relevant resource for cardiologists, cardiology fellows, and internists.
- Contents
- Beta-Blockers: The Cornerstone of Cardiac Drug Therapy -- Beta-Blocker Controversies -- Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers -- ACE Inhibitor Controversies -- Calcium Antagonists (Calcium Channel Blockers) -- Calcium Antagonist Controversies -- Diuretics -- Hypertension -- Hypertension Controversies -- Angina -- Myocardial Infarction -- Heart Failure -- Heart Failure Controversies -- Arrhythmias -- Cardiac Arrest -- Infective Endocarditis -- Dyslipidemias -- Endocrine Heart Diseases -- Antiplatelet Agents, Anticoagulants, Factor XA Inhibitors, and Thrombin Inhibitors -- Cardiac Drugs During Pregnancy and Lactation -- Drug Interactions -- Hallmark Clinical Trials -- Management of Cardiomyopathies -- Newer Agents.
- Format
- e-Book
- Publication Type
- Handbook
- Location
- Online
Principles and Practice of Controlled Ovarian Stimulation in ART
https://libcat.nshealth.ca/en/permalink/provcat39500
Surveen Ghumman, editor.
(1st ed.)
--New Delhi:
Springer India
, c2015.
- Available Online
- View e-Book
- Location
- Online
This book is on ovulation induction and controlled ovarian stimulation which is an integral part of most infertility therapies like intrauterine insemination and in vitro fertilization. It would deal with causes of anovulation and indications for ovarian stimulation. This book deals with basics as well as current and advanced practices. It provides a step by step protocol for ovarian stimulation. It gives a clear understanding of the science of reproductive endocrinology behindá these stimulati…
- Available Online
- View e-Book
- Other Authors
- Ghumman, Surveen
- Responsibility
- Surveen Ghumman, editor
- Edition
- 1st ed.
- Place of Publication
- New Delhi
- Publisher
- Springer India
- Date of Publication
- c2015
- Physical Description
- 1 online resource (xx, 421 p. : 78 illus., 63 illus. in color)
- ISBN
- 9788132216865
- 9788132216858 (print ed.)
- Subjects (MeSH)
- Ovulation Induction
- Reproductive Techniques, Assisted
- Abstract
- This book is on ovulation induction and controlled ovarian stimulation which is an integral part of most infertility therapies like intrauterine insemination and in vitro fertilization. It would deal with causes of anovulation and indications for ovarian stimulation. This book deals with basics as well as current and advanced practices. It provides a step by step protocol for ovarian stimulation. It gives a clear understanding of the science of reproductive endocrinology behindá these stimulation protocols and roadmaps the latest therapies, defining their current relevance to treatment. Besides the practical guidance it also covers latest research work done in this field. In this day of information overload it is an attempt to integrate relevant information in a manner which can be applied in infertility practice in evidence based manner, making it rational, logical and rewarding for the reader.
- Contents
- Part I. Pre Stimulation Assessment and Interventions -- 1 Detection of Ovulation and Etiology of Anovulation / Pratima Mittal and Navdeep Kaur Ghuman -- 2 Evaluation Prior to Controlled Ovarian Stimulation / Narendra Malhotra, Jaideep Malhotra, Diksha Goswami Sharma, Shilpi Gupta, Neharika Malhotra Bora, Shally Gupta, and Garima Sharma -- 3 Therapeutic Intervention of Endometrial Pathology Before Ovarian Stimulation / Lakhbir K. Dhaliwal and Shalini Gainder -- 4 Obesity and its Impact on Ovarian Stimulation / Surveen Ghumman and Pinkee Saxena -- Part II. Controlled Ovarian Stimulation: Protocols -- 5 Oral Ovulogens in IUI and IVF / Sankalp Singh, Swati Singh, and C. Mohamed Ashraf -- 6 Ovarian Stimulation in IUI / Manju Puri and Richa Aggarwal -- 7 Protocols for Gonadotropin Use / Fessy Louis Thalakottoor -- 8 Human Menopausal Gonadotropin, Pure FSH, and Recombinant FSH / Comparative Analysis- Sudha Prasad and Mona Dahiya -- 9 GnRH Agonists in Controlled Ovarian Stimulation / Hrishikesh D. Pai, Pritimala Bhalchandra Gangurde, Nandita P. Palshetkar, and Rishma Dhillon Pai -- 10 GnRH Antagonist in Ovarian Stimulation / Yakoub Khalaf and Sesh Kamal Sunkara -- 11 GnRH Agonist vs. Antagonist in ART / Madhuri Patil -- 12 Mild Stimulation Protocol / Nalini Mahajan and Shivani Singh -- 13 Individualising Ovarian Stimulation Protocols in ART / Pratap Kumar -- 14 Impact of Mutations and Polymorphisms of Gonadotrophins and Their Receptors on the Outcome of Controlled Ovarian Stimulation / Carlo Alviggi, Alessandro Conforti, and and Sandro C. Esteves -- 15 The Role of Androgens in Controlled Ovarian Stimulation / Jordana Hadassah Hyman and Ariel Revel -- 16 The Role of LH in Controlled Ovarian Simulation / Sandro C. Esteves and Carlo Alviggi -- 17 Ovulation Trigger-HCG vs. GnRH Agonist / Neeta Singh and Malti Madhu -- 18 The Pharmacoeconomics of Ovarian Stimulation / Jaideep Malhotra and Diksha Goswami Sharma -- Part III. Monitoring During Controlled Ovarian Stimulation -- 19 Endocrine Monitoring of ART Cycles / Neena Malhotra -- 20 Ultrasonography in Controlled Ovarian Stimulation / Shiri Shinar, Benny Almog, and Igal Wolman -- Part IV. The Endometrium and Luteal Phase -- 21 Effect of Ovarian Stimulation on the Endometrium / Manish Banker and Arati Gupte-Shah -- 22 Luteal Support: What to Use When? / Sandeep Talwar -- 23 Endometrial Support Beyond Hormones / Mala Arora and Shilpa Gulati -- Part V. Pathology in Controlled Ovarian Stimulation -- 24 Prediction of Poor Responders and Current Concepts in Management / Gautam N. Allahbadia and Rubina Merchant -- 25 Premature Rise of Progesterone during Ovarian Stimulation / R.K. Sharma and Arti Kapoor -- 26 Empty Follicle Syndrome / Sandeep Karunakaran -- 27 Luteinizing Unruptured Follicle / Pikee Saxena -- Part VI. Controlled Ovarian Stimulation in Gynecological Disorders -- 28 Endometriosis: Surgical Management and Optimal Ovarian Stimulation Protocol for ART / Ramandeep Kaur, Urvashi Prasad Jha, Neema Sharma, Ritambara Agrawal, and Priyata Lal -- 29 Hyperprolactinemia / Abha Majumdar and Nisha Sharma Mangal -- 30 Polycystic Ovarian Syndrome and Response to Stimulation / Nandita P. Palshetkar, Hrishikesh D. Pai, Manisha Bhagat, and Rohan Palshetkar -- 31 Role of Laparoscopic Ovarian Drilling in Polycystic Ovarian Syndrome and its Effect on ART / Pankaj Talwar, Ashok K. Pillai, and Falahunisa Shaikh -- 32 Ovulation Induction in Hypogonadotrophic Hypogonadism / Umesh Nandani Jindal and Sheetal Jindal -- 33 Ovarian Stimulation Protocols in Fertility Preservation / ankaj Talwar, Puneet Rana Arora, and Nalini Mahajan -- 34 Ovarian Stimulation in Cancer Patient / Sohani Verma -- Part VII. Negative Impact of Controlled Ovarian Stimulation -- 35 Epigenetics and Ovarian Stimulation / Jayant G. Mehta -- 36 Effect of Ovarian Stimulation Protocols on Oocyte and Embryo Quality / James Catt -- 37 Ovarian Hyperstimulation Syndrome: Can We Eliminate It as a Complication of ART? / Mala Arora and Ritika Arora -- 38 Multifetal Pregnancy Reduction / Shweta Mittal Gupta.
- Format
- e-Book
- Location
- Online
Target validation in drug discovery
https://libcat.nshealth.ca/en/permalink/provcat27190
editors, Brian W. Metcalf and Susan Dillon.
--Amsterdam, Netherlands:
Academic Press
, c2007.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Metcalf, Brian W
- Other Authors
- Dillon, Susan
- Responsibility
- editors, Brian W. Metcalf and Susan Dillon
- Place of Publication
- Amsterdam, Netherlands
- Publisher
- Academic Press
- Date of Publication
- c2007
- Physical Description
- xii, 279 p.
- ISBN
- 661070760X (electronic bk.)
- Subjects (MeSH)
- Drug Design
- Drug Delivery Systems
- Drug Evaluation
- Contents
- Cover -- Front Cover -- Table of Contents -- Preface -- Contributors -- PART I PHARMACEUTICAL BIOTECHNOLOGY FOR TARGET VALIDATION -- Chapter 1 Generation of Transgenic Animals -- I. INTRODUCTION -- II. GENERATION OF TRANSGENIC ANIMALS FOR TARGET VALIDATION -- III. CONCLUSION -- ACKNOWLEDGMENTS -- RECOMMENDED RESOURCES -- REFERENCES -- Chapter 2 Target Validation in Chemogenomics -- I. INTRODUCTION -- II. REVERSE CHEMOGENOMICS: TARGET VALIDATION USING COMPOUNDS WITH KNOWN MOLECULAR TARGET (AND/OR MECHANISM OF ACTION) -- III. FORWARD CHEMOGENOMICS: TARGET IDENTIFICATION/VALIDATION USING COMPOUNDS WITH UNKNOWN MECHANISM OF ACTION -- IV. CONCLUSION -- REFERENCES -- PART II TARGET VALIDATION FOR BIOPHARMACEUTICAL DRUG DISCOVERY -- Chapter 3 Cetuximab (Erbitux®), An Anti-Epidermal Growth Factor Receptor Antibody for the Treatment of Metastatic Colorectal Cancer -- I. INTRODUCTION -- II. EPIDERMAL GROWTH FACTOR RECEPTOR AND ITS ROLE IN HUMAN CANCER -- III. CETUXIMAB (ERBITUX®, IMC-C225) -- IV. CETUXIMAB IN CLINICAL STUDIES IN PATIENTS WITH mCRC -- V. MECHANISMS OF ACTION OF CETUXIMAB -- VI. CONCLUSIONS AND PERSPECTIVES -- RECOMMENDED RESOURCES -- REFERENCES -- Chapter 4 Monoclonal Antibody to HER-2 in Breast Cancer -- I. INTRODUCTION -- II. MECHANISM OF ACTION OF TRASTUZUMAB -- III. MOLECULAR MECHANISMS OF TRASTUZUMAB RESISTANCE -- IV. ASSESSMENT OF HER-2 STATUS -- V. CLINICAL TRIALS WITH TRASTUZUMAB -- CONCLUSION -- ACKNOWLEDGMENTS -- USEFUL WEBSITES -- REFERENCES -- Chapter 5 Validation of TNF as a Drug Target in Inflammatory Bowel Disease -- I. INTRODUCTION -- II. TUMOR NECROSIS FACTOR -- III. INFLAMMATORY BOWEL DISEASE -- IV. PATHOPHYSIOLOGY OF IBD AND THE PUTATIVE ROLE OF TNF -- V. CLINICAL EXPERIENCE WITH TNF-BLOCKING THERAPY IN IBD -- CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- Chapter 6 Anti-CCL-2/MCP-1: Directed Biologicals for Inflammatory and Malignant Diseases -- I. INTRODUCTION -- II. IN VITRO ASSAYS TO ESTABLISH THE PRO-INFLAMMATORY ACTIVITIES OF CCL-2 -- III. IN VIVO VALIDATION STUDIES -- IV. SUMMARY -- ACKNOWLEDGMENTS -- REFERENCES -- Chapter 7 Targeting IL-12p40 for Immune-Mediated Disease -- I. INTRODUCTION -- II. IN VITRO TARGET VALIDATION OF IL-12p40 -- III. IN VIVO PROOF-OF-CONCEPT FOR IL-12p40 INHIBITION -- IV. CONCLUSION -- RECOMMENDED RESOURCES -- REFERENCES -- Chapter 8 The GPIIb/IIIa Antagonist Abciximab for Acute Percutaneous Coronary Intervention -- I. INTRODUCTION -- II. RATIONALE FOR GPIIb/IIIa AS A TARGET IN CORONARY ARTERIAL DISEASE -- III. GENERATION OF THE 7E3 MONOCLONAL ANTIBODY AGAINST GPIIb/IIIa -- IV. IN VITRO STUDIES -- V. ANIMAL STUDIES -- VI. PLATELET PHARMACODYNAMIC PHENOMENA RECOGNIZED LATER -- VII. CROSS REACTIVITY WITH OTHER INTEGRINS -- VIII. INTEGRATION OF CLINICAL PHARMACOLOGY AND PRECLINICAL STUDIES -- IX. CLINICAL STUDIES -- X. CONCLUSION -- RECOMMENDED RESOURCES -- REFERENCES -- PART III VALIDATING TARGETS OF SMALL MOLECULE APPROACHES -- Chapter 9 Epidermal Growth Factor Receptor (EGFR) Inhibitor for Oncology: Discovery and Development of Erlotinib -- I. INTRODUCTION -- II. EPIDERMAL GROWTH FACTOR REC
- Format
- e-Book
- Location
- Online
A pharmacology primer : theory, applications, and methods
https://libcat.nshealth.ca/en/permalink/provcat27192
Terry Kenakin.
(2nd ed.)
--Burlington, MA:
Elsevier Academic Press
, c2006.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Kenakin, Terrence P
- Responsibility
- Terry Kenakin
- Edition
- 2nd ed.
- Place of Publication
- Burlington, MA
- Publisher
- Elsevier Academic Press
- Date of Publication
- c2006
- Physical Description
- xviii, 299 p.
- ISBN
- 6610707650 (electronic bk.)
- 9786610707652 (electronic bk.)
- Subjects (MeSH)
- Dose-Response Relationship, Drug
- Pharmacology
- Pharmacokinetics
- Receptors, Drug - physiology
- Contents
- Cover -- Front cover -- Foreword to Second Edition -- Foreword to First Edition -- Table of Contents -- 1 What Is Pharmacology? -- 1.1 About This Book -- 1.2 What Is Pharmacology? -- 1.3 The Receptor Concept -- 1.4 Pharmacological Test Systems -- 1.5 The Nature of Drug Receptors -- 1.6 Pharmacological Intervention and the Therapeutic Landscape -- 1.7 System-independent Drug Parameters: Affinity and Efficacy -- 1.8 What Is Affinity? -- 1.9 The Langmuir Adsorption Isotherm -- 1.10 What Is Efficacy? -- 1.11 Dose-response Curves -- 1.12 Chapter Summary and Conclusions -- 1.13 Derivations: Conformational Selections as a Mechanism of Efficacy -- 2 How Different Tissues Process Drug Response -- 2.1 Drug Response as Seen Through the ''Cellular Veil'' -- 2.2 The Biochemical Nature of Stimulus-response Cascades -- 2.3 The Mathematical Approximation of Stimulus-response Mechanisms -- 2.4 System Effects on Agonist Response: Full and Partial Agonists -- 2.5 Differential Cellular Response to Receptor Stimulus -- 2.6 Receptor Desensitization and Tachyphylaxis -- 2.7 The Measurement of Drug Activity -- 2.8 Advantages and Disadvantages of Different Assay Formats -- 2.9 Drug Concentration as an Independent Variable -- 2.10 Chapter Summary and Conclusions -- 2.11 Derivations -- 3 Drug-Receptor Theory -- 3.1 About This Chapter -- 3.2 Drug-Receptor Theory -- 3.3 The Use of Mathematical Models in Pharmacology -- 3.4 Some Specific Uses of Models in Pharmacology -- 3.5 Classical Model of Receptor Function -- 3.6 The Operational Model of Receptor Function -- 3.7 Two-state Theory -- 3.8 The Ternary Complex Model -- 3.9 The Extended Ternary Model -- 3.10 Constitutive Receptor Activity -- 3.11 The Cubic Ternary Complex Model -- 3.12 Chapter Summary and Conclusions -- 3.13 Derivations -- 4 Pharmacological Assay Formats: Binding -- 4.1 The Structure of This Chapter -- 4.2 Binding Theory and Experiment -- 4.3 Complex Binding Phenomena: Agonist Affinity from Binding Curves -- 4.4 Experimental Prerequisites for Correct Application of Binding Techniques -- 4.5 Chapter Summary and Conclusions -- 4.6 Derivations -- 5 Agonists: The Measurement of Affinity and Efficacy in Functional Assays -- 5.1 Functional Pharmacological Experiments -- 5.2 The Choice of Functional Assays -- 5.3 Recombinant Functional Systems -- 5.4 Functional Experiments: Dissimulation in Time -- 5.5 Experiments in Real Time Versus Stop Time -- 5.6 The Measurement of Agonist Affinity in Functional Experiments -- 5.7 Estimates of Relative Efficacy of Agonists in Functional Experiments -- 5.8 Chapter Summary and Conclusions -- 5.9 Derivations -- 6 Orthosteric Drug Antagonism -- 6.1 Introduction -- 6.2 Kinetics of Drug-Receptor Interaction -- 6.3 Surmountable Competitive Antagonism -- 6.4 Noncompetitive Antagonism -- 6.5 Agonist-Antagonist Hemi-equilibria -- 6.6 Resultant Analysis -- 6.7 Chapter Summary and Conclusions -- 6.8 Derivations -- 7 Allosteric Drug Antagonism -- 7.1 Introduction -- 7.2 The Nature of Receptor Allosterism -- 7.3 Properties of Allosteric Modulators -- 7.4 Functional Study of Allosteric Modula
- Format
- e-Book
- Location
- Online
Ovarian hyperstimulation syndrome : epidemiology, pathophysiology, prevention and management
https://libcat.nshealth.ca/en/permalink/provcat27259
Botros R. M. B. Rizk.
--Cambridge, UK:
Cambridge University Press
, 2006.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Rizk, Botros
- Responsibility
- Botros R. M. B. Rizk
- Place of Publication
- Cambridge, UK
- Publisher
- Cambridge University Press
- Date of Publication
- 2006
- Physical Description
- xiv, 233 p., [4] p. of plates
- ISBN
- 6610480001 (electronic bk.)
- Subjects (MeSH)
- Ovarian Hyperstimulation Syndrome
- Contents
- Cover -- Half-title -- Title -- Copyright -- Dedication -- Contents -- Foreword -- A complicated complication -- Preface -- I Classification of ovarian hyperstimulation syndrome -- The purpose of ovarian hyperstimulation syndrome classifications -- Overview of OHSS classifications -- The first classification of OHSS -- Reorganization of OHSS classification -- Modernization of the OHSS classification -- Designation of critical OHSS as a special entity -- Clinical classification of OHSS -- Early and late OHSS -- Spontaneous and iatrogenic OHSS -- REFERENCES -- II Epidemiology of ovarian hyperstimulation syndrome: iatrogenic and spontaneous -- The impact of in vitro fertilization on the development of OHSS -- Characterization of patients at risk of severe OHSS -- Factors that influence the incidence of OHSS -- Selection of Patients -- Polycystic ovarian syndrome -- Hyperinsulinism and OHSS -- Allergy -- Ovarian stimulation protocol -- Gonadotrophins -- Pregnant Mare Serum Gonadotrophins -- Human Pituitary Gonadotrophins -- Human Menopausal Gonadotrophin -- Purified Urinary Follicle Stimulating Hormone -- Recombinant Follicle Stimulating Hormone -- Long-acting Recombinant Follicle Stimulating Hormone -- Fixed-dose Gonadotrophins -- Clomiphene citrate -- Gonadotrophin-releasing hormone agonist -- Gonadotrophin-releasing Hormone Agonist without Gonadotrophins -- Gonadotrophin-releasing Hormone Agonist Long Protocol -- OHSS in GnRH antagonist protocols -- Luteal phase support and the role of luteal hCG in the genesis of OHSS -- OHSS and conception cycles -- Frequency of OHSS and Conception Cycles -- Duration of OHSS and Conception Cycles -- Spontaneous OHSS -- Time course development of spontaneous OHSS -- Spontaneous OHSS and hCG levels -- Recurrent OHSS -- Familial OHSS -- Hypothyroidism and OHSS -- Spontaneous OHSS and DVT -- The role of an OHSS registry -- REFERENCES -- III Pathophysiology of ovarian hyperstimulation syndrome -- Role of peripheral arteriolar dilatation -- Osmoregulation in patients with OHSS -- Increased erythrocyte aggregation in OHSS -- Immunoglobulins in OHSS -- Source of the peritoneal fluid -- Mediators of increased capillary permeability -- Estrogens -- Progesterone -- The Ovarian Renin-Angiotensin System -- Studies of Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers -- Prostaglandins -- von Willebrand Factor -- Endothelin-1 -- Vascular endothelial growth factor -- Discovery and Cloning -- VEGF receptors -- Tyrosine Kinase Receptors -- VEGF165 Specific Receptor Neuropilin-1 -- VEGF gene expression -- Regulation of VEGF production -- VEGF Isoforms -- Role of VEGF in Physiological and Pathological States -- What is the link between VEGF and OHSS? -- VEGF as a capillary permeability agent in OHSS -- VEGF mRNA expression in the rat and primate ovary -- VEGF m-RNA Expression in Human Luteinized Granulosa Cells -- VEGF Dynamic Studies and OHSS -- VEGF in Follicular Fluid and GnRH Antagonist -- VEGF Soluble Receptor -- Free VEGF or Total VEGF
- Format
- e-Book
- Location
- Online
